Home  |  Contact

Cellosaurus ZR-75-1 GDC-0941-resistant (CVCL_A1FN)

[Text version]

Cell line name ZR-75-1 GDC-0941-resistant
Accession CVCL_A1FN
Resource Identification Initiative To cite this cell line use: ZR-75-1 GDC-0941-resistant (RRID:CVCL_A1FN)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:65326; Pictrelisib (Pictilisib; GDC-0941).
Sequence variations Mutation; HGNC; 8976; PIK3CB; Simple; p.Asp1067Tyr (c.3199G>T); Zygosity=Heterozygous; Note=Responsible for pictrelisib resistance (PubMed=26759240).
Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line).
Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line).
Disease Invasive breast carcinoma of no special type (NCIt: C4194)
Derived from metastatic site: Ascites.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0588 (ZR-75-1)
Sex of cell Female
Age at sampling 63Y
Category Cancer cell line
Publications

PubMed=26759240; DOI=10.1158/0008-5472.CAN-15-2201
Nakanishi Y., Walter K., Spoerke J.M., O'Brien C., Huw L.Y., Hampton G.M., Lackner M.R.
Activating mutations in PIK3CB confer resistance to PI3K inhibition and define a novel oncogenic role for p110beta.
Cancer Res. 76:1193-1203(2016)

Cross-references
Other Wikidata; Q102115154
Polymorphism and mutation databases Cosmic; 2787557
Entry history
Entry creation29-Oct-2020
Last entry update23-Sep-2021
Version number4